Amgen and AstraZeneca strengthen Tezspire’s expansion case with full esophagitis trial results

Amgen and AstraZeneca announced full results from the Phase 3 CROSSING trial of Tezspire on October 20. The late-stage study enrolled adolescents and adults with symptomatic, uncontrolled eosinophilic esophagitis, a disease that inflames the esophagus and can make swallowing difficult. It tested injections under the skin every four weeks at doses of 210 mg and 420 mg.^[1]

The companies said Tezspire significantly improved symptoms and measures of inflammation in tissue compared with placebo at week 24, with benefits sustained through week 52. At week 52, it also significantly improved total endoscopic remission—meaning examination showed no visible inflammation or fibrosis, or scarring. This is a trial-results announcement, not an announcement of approval for this use.^[1]

The data strengthen the case for taking Tezspire beyond asthma into another disease: benefits in symptoms and tissue measures lasted a year, rather than resting on a short-term response. If approved for this use, it could give doctors another treatment option and Amgen and AstraZeneca another source of sales.^[1][2]

Clinical evidence is not yet a commercial return. Revenue would still depend on insurance coverage, prescribing and patient uptake after approval. The trial did not establish superiority to existing medicines, so it cannot show how much market share Tezspire might win.^[1][3]

Impact